Burning Mouth Syndrome (BMS) is a chronic pain condition characterized by persistent intraoral burning without related objective findings and unknown etiology that affects elderly females mostly. There is no satisfactory treatment for BMS. We aimed to observe the long-term efficacy of high velanfaxine doses combined with systemic and topical administered clonazepam in a particular subgroup of BMS patients who do not respond to current clinical management.
Eight (66.1 ± 6.2 years old females) out of 14 BMS patients fulfilled the inclusion criteria and were treated with venlafaxine (300 mg/d) and clonazepam (5 mg/d) for 35.4 ± 12.1 (mean ± SD) months. The average duration of the symptoms at baseline was 4.3 ± 1.4 years and the overall mean daily pain intensity score was 8.6 ± 1.3 (VAS); pain was in tongue and within the oral mucosa, accompanying by oral and facial dysesthesia. In five patients tasting was abnormal. All patients had positive history of concomitant primary headache. The average score of Hamilton Rating scale for Anxiety and Depression was 21 ± 4.2, and 26.1 ± 2.9, respectively. Previous ineffective treatments include anticonvulsants and anti-depressants. All patients responded (more than 50% decrease in VAS) after three months treatment (mean VAS 3.2 ± 2.2) with no remarkable adverse events.
BMS deserves bottomless psychiatric evaluation and management when current available treatments fail. Treatment with venlafaxine combined with topical and systemic clonazepam may be effective in refractory BMS cases but further investigation in a large-scale controlled study is needed to confirm these results.
Headache Classification Committee of the International Headache Society (IHS). International Classification of Headache Disorders, 3 rd edition. Cephalalgia 2013;33:629-808.
Kohorst JJ, Bruce AJ, Torgerson RR, Schenck LA, Davis MD (2014) The prevalence of burning mouth syndrome: a population-based study. Br J Dermatol 89:1545–52
Koike K, Shinozaki T, Hara K, Noma N, Okada-Ogawa A, Asano M, Shinoda M, Eliav E, Gracely RH, Iwata K, Imamura Y (2014) Immune and endocrine function in patients with burning mouth syndrome. Clin J Pain 30:168–173 PubMed
Spanemberg JC, Rodríguez de Rivera Campillo E, Salas EJ, López López J (2014) Burning Mouth Syndrome: update. Oral Health Dent Manag 13:418–424 PubMed
Borsani E, Majorana A, Cocchi MA, Conti G, Bonadeo S, Padovani A, Lauria G, Bardellini E, Rezzani R, Rodella LF (2014) Epithelial expression of vanilloid and cannabinoid receptors: a potential role in burning mouth syndrome pathogenesis. Histol Histopathol 29:523–533 PubMed
Prakash S, Ahuja S, Rathod C (2012) Dopa responsive burning mouth syndrome: restless mouth syndrome or oral variant of restless legs syndrome?J. Neurol Sci 320:156–156 CrossRef
McMillan R, Forssell H, Buchanan JA, Glenny AM, Weldon JC, Zakrzewska JM (2016) Interventions for treating burning mouth syndrome. Cochrane Database Syst Rev 11:CD002779 PubMed
Amos K, Yeoh SC, Farah CS (2011) Combined topical and systemic clonazepam therapy for the management of burning mouth syndrome: a retrospective pilot study. J Orofac Pain 25:125–30 PubMed
Besson M, Matthey A, Daali Y, Poncet A, Vuilleumier P, Curatolo M, Zeilhofer HU, Desmeules J (2015) GABAergic modulation in central sensitization in humans: a randomized placebo-controlled pharmacokinetic-pharmacodynamic study comparing clobazam with clonazepam in healthy volunteers. Pain 156:397–404 CrossRefPubMed
Kacirova I, Grundmann M, Silhan P, Brozmanova H (2016) A case report of clonazepam dependence: utilization of therapeutic drug monitoring during withdrawal period. Medicine (Baltimore) 95(9):e2881 CrossRef
Aiyer R, Barkin RL, Bhatia A. Treatment of Neuropathic Pain with Venlafaxine: A Systematic Review. Pain Med. 2016. [Epub ahead of print]
Richards JS, Bombardier CH, Wilson CS, Chiodo AE, Brooks L, Tate DG, Temkin NR, Barber JK, Heinemann AW, McCullumsmith C, Fann JR (2015) Efficacy of venlafaxine XR for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial. Arch Phys Med Rehabil 96:680–9 CrossRefPubMed
Mignogna MD, Pollio A, Fortuna G, Leuci S, Ruoppo E, Adamo D, Zarrelli C (2011) Unexplained somatic comorbidities in patients with burning mouth syndrome: a controlled clinical study. J Orofac Pain 25:131–40 PubMed
- Refractory burning mouth syndrome: clinical and paraclinical evaluation, comorbidities, treatment and outcome
Dimos D. Mitsikostas
Christina I. Deligianni
- Springer Milan
Neu im Fachgebiet AINS
Meistgelesene Bücher aus dem Fachgebiet AINS
Mail Icon II